Who are Lidocaine HCl 1%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ropivacaine only, Exparel + Bupivacaine, ESL, Ropivacaine + Dexmedetomidine, Prilocaine 0.66%, postoperative 0.5% Ropivacaine hydrochloride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lidocaine-hcl-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Lidocaine HCl 1% — Competitive Intelligence Brief

Lidocaine HCl 1% (Lidocaine HCl 1%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Anesthesia.

marketed Local anesthetic Voltage-gated sodium channels Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Lidocaine HCl 1% (Lidocaine HCl 1%) — HaEmek Medical Center, Israel. Lidocaine HCl blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lidocaine HCl 1% TARGET	Lidocaine HCl 1%	HaEmek Medical Center, Israel	marketed	Local anesthetic	Voltage-gated sodium channels
Ropivacaine only	Ropivacaine only	University of New Mexico	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Exparel + Bupivacaine	Exparel + Bupivacaine	Pacira Pharmaceuticals, Inc	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
ESL	ESL	Bial - Portela C S.A.	marketed	Voltage-gated sodium channel blocker; anticonvulsant	Voltage-gated sodium channels (Nav)
Ropivacaine + Dexmedetomidine	Ropivacaine + Dexmedetomidine	Sahiwal medical college sahiwal	marketed	Local anesthetic + alpha-2 adrenergic agonist combination	Voltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (dexmedetomidine)
Prilocaine 0.66%	Prilocaine 0.66%	Bozyaka Training and Research Hospital	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
postoperative 0.5% Ropivacaine hydrochloride	postoperative 0.5% Ropivacaine hydrochloride	China Medical University, China	marketed	Local anesthetic (amide)	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

University of California, San Diego · 3 drugs in this class
Durect · 3 drugs in this class
Pacira Pharmaceuticals, Inc · 3 drugs in this class
Wake Forest University Health Sciences · 3 drugs in this class
Medical University of Vienna · 3 drugs in this class
Imperial College London · 2 drugs in this class
Hvidovre University Hospital · 2 drugs in this class
Innocoll · 2 drugs in this class
George Washington University · 2 drugs in this class
Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lidocaine HCl 1% — Competitive Intelligence Brief. https://druglandscape.com/ci/lidocaine-hcl-1. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab